Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Clinical variables and management of disseminated granuloma annulare - monocentric retrospective analysis of 33 cases between 2021 and 2023].
Dermatologie (Heidelb)
January 2025
Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland.
Article Synopsis
- Granuloma annulare (GA) is a non-infectious skin condition that can become widespread in some patients; this study focused on those with disseminated GA in a German hospital.
- A total of 239 patients were studied, with 33 having confirmed disseminated GA, predominantly affecting women around the age of 57, and many reporting little to no symptoms.
- Treatment options included glucocorticoids and phototherapy, but only a small percentage achieved remission, highlighting the need for more effective clinical trials for new therapies.
Treatment of disseminated granuloma annulare with pulse therapy upadacitinib.
Dermatol Online J
October 2024
Hudson Dermatology, Kingston, New York, USA.
Granuloma annulare (GA) is an idiopathic inflammatory skin condition with a chronic and unpredictable course. Although localized GA is usually cleared with topical or systemic corticosteroids, generalized GA is often difficult to treat owing to the lack of treatment options and recurrence with treatment. Recent evidence has helped to elucidate the etiology behind GA, with growing confirmation for the use of JAK inhibitors as a possible treatment for GA.
View Article and Find Full Text PDFThis case report describes a 34-year-old, HIV-positive, female referred to the hospital for treatment. The patient had widespread Kaposi sarcoma and a very low CD4-number. Prior to diagnosis, she had generalized granuloma annulare for six months, an incident of herpes zoster, and no sexual risk behaviour.
View Article and Find Full Text PDFDrug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica.
JID Innov
November 2024
Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.
Article Synopsis
- Drug repurposing offers a cost-effective strategy for developing therapies for rare diseases, which often face challenges in traditional drug development.
- This study used a new drug identification and repurposing pipeline to discover molecular drivers and potential therapies for psoriasis, leading to the identification of both known and novel disease mechanisms.
- The approach was further applied to necrobiosis lipoidica, revealing important disease drivers and potential treatments, demonstrating a high success rate in matching drugs to identified molecular targets.
Effective Treatment of Recalcitrant Generalized Papular Granuloma Annulare With Upadacitinib Monotherapy: A Case Report and Literature Review.
Skin Res Technol
October 2024
Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!